Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry
James R
JR
Division of Neurology, Sunnybrook Health Sciences Center, Room A402, 2075 Bayview Ave, Toronto, Ontario, Canada M4N 3M5. james.perry@sunnybrook.ca
Bélanger
Karl
K
Mason
Warren P
WP
Fulton
Dorcas
D
Kavan
Petr
P
Easaw
Jacob
J
Shields
Claude
C
Kirby
Sarah
S
Macdonald
David R
DR
Eisenstat
David D
DD
Thiessen
Brian
B
Forsyth
Peter
P
Pouliot
Jean-François
JF
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000009:adverse effects; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D002170:Canada; D017024:Chemotherapy, Adjuvant; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018714:Radiotherapy, Adjuvant; D012008:Recurrence; D000077204:Temozolomide; D013997:Time Factors; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide